We report three patients who presented with chest pain after receiving either the BNT162b2
Pfizer/BioNTech or mRNA‐1273 Moderna/NIH vaccine. Clinical presentation, biomarker …

Introduction The etiology of myocarditis often remains undetermined. A large variety of
infectious agents, systemic diseases, drugs, and toxins can cause the disease. We report the …

Background Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report
six cases of myocarditis, which occurred shortly after BNT162b2 vaccination. Methods …

COVID-19 infection has cardiovascular manifestations such as acute myocarditis,
arrhythmia, ischemic cardiomyopathy, heart failure, pericardial effusion, cardiac tamponade …

Two reports in the current issue of JAMA Cardiology describe cases of acute myocarditis that
occurred among persons who received the BNT162b2-mRNA (Pfizer-BioNTech) or mRNA …

With the introduction of the coronavirus disease 2019 (COVID-19) mRNA vaccines, the
incidence of severe infection has significantly decreased. While the vaccines have been …

Background and objectives According to some reports, there is a link between the
development of myocarditis and the administration of messenger RNA (mRNA) vaccines …

Methods This is an observational case series of patients who were diagnosed with
myocarditis after mRNA COVID-19 vaccination. The clinical characteristics, short term (4–6 …

Background Association between messenger RNA (mRNA) COVID-19 vaccines and
myocarditis has aroused public concern over vaccine safety. Objectives The goal of this …

Myocarditis is now recognized as a rare complication of coronavirus disease 2019 (COVID-
19) mRNA vaccination, particularly in adolescent and young adult males. Since the …